Why the study?
Is the Elixir DESolve Novolimus-eluting bioresorbable coronary scaffold system safe and effective for the treatment of coronary lesions?
Is the Elixir DESolve Novolimus-eluting bioresorbable coronary scaffold system safe and effective for the treatment of coronary lesions?
The DESolve Novolimus-eluting bioresorbable scaffold appears safe and effective at 12 months for treating coronary lesions in a post-marketing evaluation.
Answers are grounded in this paper and cite their sources.
Supports DESolve BRS at 12 months in real-world use; extends observational data but leaves open confirmation by randomized trials.
Results through 12 months indicate that the DESolve BRS is a safe and effective treatment for coronary lesions, though larger, long-term prospective studies are needed.
No takes yet. Share an insight, caveat, or question.
Nef et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: